What Psilocybin Actually Does to the Human Brain: New Research Reveals Measurable Changes After a Single Dose
- Phil O'Zybyn
- 1 day ago
- 14 min read
What Psilocybin Actually Does to the Human Brain: New Research Reveals Measurable Changes After a Single Dose
A landmark 2026 study published in Nature Communications used EEG and MRI to track what happens to the human brain in the hours, weeks, and months after a first high-dose psilocybin experience. The findings are the clearest evidence yet that psilocybin produces real, measurable neurological changes — not just subjective ones.
Category: Research and Microdosing | /7-research-and-microdosing
Source study: Lyons et al. (2026). Human brain changes after first psilocybin use. Nature Communications, 17, 3977. https://doi.org/10.1038/s41467-026-71962-3
Research institution: Centre for Psychedelic Research, Imperial College London & UCSF
Keywords: psilocybin research, psilocybe mushrooms, fungal biology, mycology science, microdosing research, mushroom education, neuroplasticity, brain entropy, psilocybin neuroimaging, psychedelic research Canada
Read time: ~12 minutes
Published by: Spores Lab | sporeslab.io
Research note: Spores Lab sells Psilocybe spore products for microscopy and taxonomic research purposes only. Psilocybe spores are legal to possess for research in Canada; cultivation laws vary by jurisdiction. This blog discusses peer-reviewed scientific research on psilocybin. It does not constitute medical advice or encourage illegal activity.
What Psilocybin Actually Does to the Human Brain: New Research Reveals Measurable Changes After a Single Dose
For decades, most of what we knew about psilocybin's effects on the human brain came from subjective reports — participants describing vivid experiences, altered perceptions of time, feelings of profound interconnectedness, or deep psychological insight. These reports were consistent and compelling, but they were not the same as hard neurological evidence. They couldn't tell us whether the brain was actually changing in measurable, physical ways — or whether the psychological experience was simply that: an experience, leaving no detectable biological trace.
A study published in Nature Communications in May 2026 changes that picture significantly. Led by researchers at the Centre for Psychedelic Research at Imperial College London and the University of California San Francisco, the study is the first to use a multimodal neuroimaging design — combining EEG, fMRI, and diffusion tensor imaging (DTI) — to track brain changes from one hour to one month after a single high-dose psilocybin experience in healthy, psychedelic-naive participants. The results are some of the most detailed and direct evidence yet of psilocybin's neurological impact on the human brain.
This blog breaks down exactly what the researchers found, what it means in plain terms, and why it matters for anyone interested in the frontier of psilocybe mushroom research and mycology science.
The Study: What Was Done and How
The study enrolled 28 healthy adult volunteers — average age 41, none of whom had ever taken a psychedelic substance before. This was a critical design choice: by studying first-time users, the researchers could observe the brain's unmediated response to psilocybin, without any prior experience that might alter baseline neural patterns.
Each participant received two oral doses of psilocybin, one month apart, in a fixed order:
• 1 mg psilocybin — a sub-threshold control dose, functionally a placebo (confirmed by EEG data showing no measurable brain effects)
• 25 mg psilocybin — a high, fully active dose capable of inducing a complete psychedelic experience
Brain imaging took place across three scanning sessions — at baseline, one month after the 1 mg dose, and one month after the 25 mg dose. EEG was recorded during the dosing sessions themselves, at 1, 2, and 4.5 hours post-dose. Psychological outcomes — including cognitive flexibility, psychological insight, and psychological well-being — were measured at multiple timepoints.
The study was exploratory and hypothesis-generating in design — the researchers were looking at a broad range of neurological and psychological measures simultaneously, using rigorous statistical correction, to build a picture of what 25 mg psilocybin actually does to a healthy human brain over time. Here is what they found.
STUDY REFERENCE: Lyons T, Spriggs M, et al. (2026). Human brain changes after first psilocybin use. Nature Communications, 17, 3977. doi: 10.1038/s41467-026-71962-3
Finding 1: Psilocybin Dramatically Increases Brain Entropy — And This Predicts Well-Being One Month Later
The most striking acute finding was a dramatic and statistically significant increase in brain entropy — measured as Lempel-Ziv complexity (LZc) — in the EEG signal during the 25 mg psilocybin session. Brain entropy, in this context, refers to the statistical irregularity or informational complexity of spontaneous brain activity. Higher entropy means the brain is generating more complex, less predictable, less compressible patterns of electrical activity.
This increase was large and dose-specific: it occurred only under 25 mg psilocybin, not under the 1 mg control. It peaked at the 2-hour mark — coinciding with participants' self-reported peak of subjective intensity — and was accompanied by significant decreases in alpha power, a well-established marker of psilocybin's acute brain effects linked to cortical disinhibition.
Why this matters: Brain entropy under psilocybin is not just an interesting observation. The study found that the level of brain entropy at 2 hours post-dose significantly predicted two important outcomes measured much later:
• Next-day psychological insight (r = 0.59, p = 0.006) — participants whose brains showed greater entropy at the 2-hour mark reported greater psychological insight the following day
• Well-being at one month (r = 0.66, p = 0.006) — the same acute entropy measure predicted improvements in psychological well-being a full month after the session
The predictive path was further clarified by a mediation analysis: acute brain entropy predicted next-day psychological insight, which then predicted one-month improvements in well-being. In other words, the brain's acute response to psilocybin — measurable by EEG within the first two hours — sets in motion a chain of psychological changes that persist for at least a month.
This is a clear and important conclusion: the acute neurological experience of psilocybin is not incidental to its psychological effects — it is mechanistically linked to them. The brain change predicts the mind change.
Finding 2: Psilocybin Produces Measurable Anatomical Changes in White Matter Tracts
Perhaps the most significant anatomical finding of the study was observed through diffusion tensor imaging (DTI) — a brain scanning technique that measures the movement of water molecules through white matter fibres to infer their structural integrity and density. DTI revealed significant changes in axial diffusivity — the diffusion coefficient along the principal direction of nerve fibers — one month after the 25 mg psilocybin session.
Specifically, axial diffusivity decreased significantly in two bilateral white matter tracts:
• Prefrontal cortex — striatum tract (PFC-STR): a pathway involved in decision-making, reward processing, and behavioural flexibility
• Prefrontal cortex — thalamus tract (PFC-THA): a pathway involved in sensory gating, attention, and the regulation of conscious experience
These decreases in axial diffusivity — measured one month after a single 25 mg dose — were significant, robust to statistical correction, and exclusive to the 25 mg condition. The 1 mg control produced no measurable DTI changes at any timepoint.
The two affected tracts share substantial spatial overlap, suggesting the changes likely share a common origin in the prefrontal cortex — the region with the highest density of serotonin 2A receptors (5-HT2ARs) in the human brain, and the primary receptor target through which psilocybin is understood to produce its effects.
What Does Decreased Axial Diffusivity Mean?
Interpreting DTI data requires care — the researchers themselves emphasise this. Changes in axial diffusivity can reflect several different biological events, including changes in axon density, membrane permeability, myelination, glial growth, or extracellular fluid. They do not map one-to-one onto a single anatomical change.
However, the researchers offer a tentative interpretation, consistent with preclinical animal research: these DTI changes may represent evidence of anatomical neuroplasticity in the human brain following psilocybin. Specifically, the findings echo earlier animal studies showing that single-dose psilocybin produces rapid and persistent growth of dendritic spines in the frontal cortex of mice (Shao et al., 2021) and increased synaptic density in pigs (Raval et al., 2021).
If the DTI findings reflect microstructural changes — and they are consistent with that interpretation, though not definitively proven — two types of change are plausible: the pruning of weak or redundant neural connections, and/or the formation of new, under-myelinated axonal connections. Both would be consistent with a brain reorganising its connectivity after a profound and disruptive neurological experience.
The clear conclusion: a single high dose of psilocybin produced detectable changes in the white matter structure of the prefrontal cortex pathways, measurable one month later. Whether these reflect full anatomical neuroplasticity requires replication — but the signal is present, consistent, and dose-exclusive.
KEY FINDING: Decreased axial diffusivity in PFC-STR and PFC-THA tracts at one month post-25mg psilocybin. Not seen after 1mg control. Robust to free-water correction. Correlated with reduced brain network modularity.
Finding 3: Brain Network Modularity Decreases — and This Correlates With Improved Well-Being
The study also examined brain network modularity — a measure of how segmented or 'siloed' the brain's functional networks are. High modularity means different brain networks communicate relatively independently of each other. Low modularity means a more globally integrated, less segregated brain — different regions communicating more freely across usual boundaries.
One month after the 25 mg session, brain network modularity showed a significant decrease when compared against pre-dose baseline (p = 0.007, d = 0.6). This decrease — a movement toward more integrated, less siloed brain connectivity — negatively correlated with improvements in well-being (r = −0.40, p = 0.04): participants whose brains became more globally integrated showed the greatest improvements in psychological well-being.
This finding is directly consistent with earlier research. Two separate psilocybin-therapy trials for depression found the same pattern: decreased brain network modularity post-treatment correlating with improvements in depressive symptom severity. The present study, conducted in healthy volunteers rather than depressed patients, shows the same directional relationship — reduced modularity correlating with improved mental health — in a non-clinical sample.
Notably, the DTI-measured axial diffusivity decreases also correlated with the modularity changes, suggesting these anatomical and functional changes are related. A brain whose white matter connectivity is shifting in the prefrontal pathways is also a brain becoming more globally integrated functionally.
The clear conclusion: psilocybin moves the brain toward greater functional integration. This integration correlates with improved psychological well-being. The pattern is now replicated across multiple independent studies in both clinical and healthy populations.
Finding 4: Cognitive Flexibility Increases at One Month
Cognitive flexibility — the brain's ability to shift attention between rules and adapt behaviour when rules change — was assessed using a validated intra-dimensional/extra-dimensional (IDED) attentional set-shifting task. The key measure was the extradimensional shift (EDS): the ability to correctly identify and act on a new rule when a fundamental shift occurs, rather than perseverating on an old pattern.
One month after the 25 mg session, participants made significantly fewer errors on the EDS stage of the task (p = 0.016, d = 0.5) — indicating meaningfully greater cognitive flexibility than at one month after the 1 mg control. This change was specific to attentional set-shifting (flexible adaptation) rather than reflecting a general improvement in task performance or a simple practice effect.
Cognitive flexibility is clinically relevant: reduced cognitive flexibility is a core feature of depression, OCD, addiction, and several anxiety disorders. The finding that a single high dose of psilocybin produces measurable improvements in cognitive flexibility in healthy adults — persisting for at least one month — adds important evidence to the growing body of research on psilocybin's cognitive effects.
The clear conclusion: one month after a single 25 mg psilocybin dose, healthy adults show measurably better cognitive flexibility. They adapt more readily when rules change. They perseverate less. This is not a subjective impression — it is a behavioural measure, objectively scored.
Finding 5: Psychological Insight and Well-Being Improve — and Persist
The psychological outcome data are striking in their consistency and duration. Across validated measures at multiple timepoints:
Psychological insight (measured via the Psychological Insight Scale, PIS): scores were significantly higher after 25 mg vs 1 mg at all three post-dose timepoints — one day (d = 1.9), two weeks (d = 1.3), and one month (d = 1.2). These are large effect sizes, and the persistence of elevated insight for a full month after a single dose is notable.
Psychological well-being (measured via the Warwick-Edinburgh Mental Wellbeing Scale, WEMWBS): significant improvements at two weeks (d = 0.8) and one month (d = 0.6) after the 25 mg session. No changes at any timepoint after the 1 mg control.
Ninety-four percent of participants rated their 25 mg experience as the single most unusual state of consciousness of their entire lives. The remaining participant ranked it among their top five. In contrast, most participants rated the 1 mg experience as no more unusual than an everyday state — confirming that the placebo dose was genuinely inactive, and that all observed changes are attributable to the 25 mg condition.
The clear conclusion: a single high-dose psilocybin experience produces lasting improvements in psychological insight and well-being in healthy adults. These improvements are not fleeting. They are measurable at one month by validated psychological scales. And they are predicted by — and mechanistically linked to — the acute neurological changes observed hours earlier.
What the Study Does Not Claim
The researchers are appropriately careful about what their findings do and do not establish. Several important caveats:
• The fMRI functional results were modest. Most resting-state functional connectivity analyses did not reach statistical significance. The functional brain changes detected at one month were less robust than those observed in studies of psilocybin therapy for depression. The researchers suggest this may reflect the fact that healthy brains — without baseline pathology — have less room for functional remediation, or that existing measurement tools are not yet sensitive enough to detect subtle functional changes in non-clinical populations.
• The DTI findings require replication. The anatomical white matter findings are novel and suggestive, but interpretation of axial diffusivity changes is complex. The researchers explicitly call for follow-up studies using multi-shell DTI sequences to confirm and characterise these findings.
• The study was exploratory, not pre-registered. This is appropriate for a study of this scope and novelty, but it means results should be interpreted as hypothesis-generating rather than hypothesis-confirming. Between-subjects confirmatory studies are the needed next step.
• Small sample size. 28 participants is a meaningful sample for a neuroimaging study of this kind, but replication in larger samples is essential before strong causal claims can be made.
None of these caveats diminish the significance of the findings. They contextualise them. The study is rigorous, peer-reviewed, published in one of the world's leading scientific journals, and produced by one of the most experienced research teams in the field. Its conclusions are well-supported by the data it presents.
Why This Research Matters — and What Comes Next
The significance of this study extends beyond the specific findings. It establishes several important things for the broader field of psilocybin research and mycology science:
The acute experience matters mechanistically. The finding that EEG-measured brain entropy at 2 hours predicts well-being at one month is not a correlation between two independent events. It is a predictive, mediated chain. The brain's acute response to psilocybin — the 'psychedelic experience' as a neurological event — is mechanistically involved in producing the longer-term psychological changes. This validates the scientific importance of the subjective experience, not just the pharmacology.
Healthy brains change too. Most psilocybin neuroimaging research has focused on clinical populations — people with depression, anxiety, PTSD, or addiction. This study shows that anatomical and psychological changes occur in healthy volunteers with no baseline pathology. The magnitude of change is different from clinical studies, but the direction is consistent.
The serotonin 2A receptor is central. The prefrontal cortex concentration of 5-HT2A receptors — the primary target of psilocybin's active metabolite psilocin — appears to be the key anatomical locus for the observed white matter changes. This is consistent with the broader pharmacological understanding of psilocybe mushroom biochemistry and points toward mechanistically targeted future research.
Brain entropy is a reliable biomarker. The predictive power of brain entropy — measured acutely by EEG — for downstream psychological outcomes makes it a potentially powerful biomarker for psilocybin research. Future studies can use this relationship to design more targeted protocols and to predict individual-level therapeutic outcomes.
The Canadian Research Context
For researchers and mycology science enthusiasts in Canada, this study is particularly relevant. Canada is one of a small number of countries where the research and policy landscape around psilocybe mushroom research has been actively evolving. Health Canada has granted exemptions for psilocybin use in therapeutic contexts, and several Canadian research programmes are examining psilocybin-assisted therapy for a range of conditions.
The spore research supply chain — including suppliers like Spores Lab — exists at the microscopy and taxonomic research end of this ecosystem. Understanding what psilocybin does at the neurological level is directly relevant to anyone in the Canadian mycology research community who wants to understand why this compound is attracting the level of scientific attention it is. The 2026 Nature Communications study provides the most detailed, direct answer yet.
Explore the Full Research & Microdosing Pillar
This blog is part of Spores Lab's Research and Microdosing pillar — our growing library of science-forward content on psilocybe biology, neurological research, and the evolving evidence base around microdosing and therapeutic applications. Related reading across our seven content pillars: Mushroom Growing Basics for foundational cultivation knowledge; Substrate Preparation and Contamination & Sterile Technique for clean, research-grade cultivation practice; Growing Environment for environmental control across psilocybe and edible species; Mushroom Genetics & Strains for a deep dive into Psilocybe cubensis strain profiles; Growing Equipment for laboratory-grade tool guidance; and Research and Microdosing for peer-reviewed science content like this article. Explore the full library at sporeslab.io/blog.
Key Conclusions: What the Research Establishes
1. Brain entropy increases dramatically under high-dose psilocybin — and the magnitude of this acute neurological change predicts psychological insight the next day and improved well-being one month later. The experience is mechanistically linked to the outcome.
2. A single 25 mg psilocybin dose produces detectable changes in white matter structure — specifically decreased axial diffusivity in prefrontal-subcortical tracts — measurable one month later. This may represent evidence of anatomical neuroplasticity in the human brain.
3. Brain network modularity decreases after psilocybin — the brain becomes more globally integrated, less siloed. This decreased modularity correlates with improved psychological well-being, replicating findings from two independent psilocybin-for-depression trials.
4. Cognitive flexibility improves measurably at one month — healthy adults make fewer errors on an attentional set-shifting task, indicating a genuine improvement in the brain's ability to adapt when rules change.
5. Psychological insight and well-being improve durably — both are elevated at two weeks and one month post-dose, with large effect sizes, measured by validated psychological scales.
6. All effects are exclusive to the 25 mg dose — the 1 mg control produced no measurable brain changes, no psychological improvements, and no DTI findings at any timepoint. The changes are dose-dependent and pharmacologically specific.
FAQ: Psilocybin and Brain Research
Q: What is psilocybin and how does it affect the brain?
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring compound found in several species of the genus Psilocybe, including Psilocybe cubensis. After ingestion, it is metabolised to psilocin, which acts as a potent agonist at serotonin 2A receptors (5-HT2ARs) — particularly concentrated in the human prefrontal cortex. This receptor activation is understood to be the primary mechanism through which psilocybin produces its characteristic acute brain and psychological effects, including increased brain entropy, decreased alpha power, altered sensory processing, and the subjective 'psychedelic experience'.
Q: What does 'brain entropy' mean and why does it matter?
Brain entropy, as measured in this study, refers to the statistical complexity or unpredictability of the brain's spontaneous electrical activity. Higher entropy means the brain is generating more varied, less repetitive, less predictable patterns. Under psilocybin, the brain's activity becomes measurably more complex — less constrained by its usual patterns. The Lyons et al. study found that the degree of this entropy increase acutely predicts both psychological insight and well-being improvements at one month, making it one of the most significant mechanistic findings in recent psilocybin neuroimaging research.
Q: What is diffusion tensor imaging and what did it show in this study?
DTI (diffusion tensor imaging) is a type of MRI that measures the movement of water molecules through white matter fibres in the brain. Because water diffuses more freely along the length of nerve fibres than across them, DTI can infer the structural organisation and integrity of white matter tracts. In this study, DTI revealed decreased axial diffusivity — movement along the principal fibre direction — in two prefrontal-subcortical white matter tracts one month after 25 mg psilocybin. This finding is tentatively interpreted as evidence of microstructural change in the brain's white matter, possibly reflecting anatomical neuroplasticity.
Q: Does this research prove that psilocybin causes neuroplasticity in humans?
The study provides suggestive evidence that psilocybin produces microstructural brain changes consistent with neuroplasticity — specifically the DTI findings in prefrontal white matter tracts. This is consistent with animal studies showing synaptogenesis and dendritic spine growth after single-dose psilocybin. However, the researchers are appropriately cautious: DTI changes can reflect multiple biological processes, and these specific findings have not yet been independently replicated. The conclusion supported by the data is that psilocybin produces detectable structural brain changes — whether these represent full anatomical neuroplasticity requires further confirmation.
Q: Is psilocybin research legal in Canada?
Psilocybin is a controlled substance in Canada under the Controlled Drugs and Substances Act. However, Health Canada has the authority to grant exemptions for research, therapeutic, and other purposes — and has done so in a growing number of contexts. Psilocybe spores, which do not contain psilocybin or psilocin, are legal to possess for microscopy and taxonomic research purposes in Canada. Spores Lab sells products for microscopy and research use only. For specific legal questions about psilocybin research in your jurisdiction, consult a legal professional or Health Canada directly.
Q: What does this mean for microdosing research?
This study used a high dose (25 mg) rather than a microdose, and the findings are specific to that dose level — the 1 mg control produced no measurable effects. The research does not directly address microdosing protocols. However, it is relevant to microdosing research in two ways: it establishes robust mechanistic evidence that psilocybin produces neurological changes through its 5-HT2AR action, and it provides a framework (brain entropy, network modularity, cognitive flexibility) that future microdosing studies could use to evaluate whether sub-perceptual doses produce similar, if smaller, neurological effects.
Explore psilocybe genetics and research at Spores Lab.
Browse viability-tested Psilocybe cubensis spore products for microscopy and research at sporeslab.io/shop. Explore the full Research and Microdosing pillar and all seven blog categories at sporeslab.io/blog.
Comments